MAT 100

Drug Profile

MAT 100

Alternative Names: Bone fracture GAM gene delivery

Latest Information Update: 26 Apr 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tissue Repair Company
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Fracture

Most Recent Events

  • 15 Apr 2005 No development reported - Preclinical for Fracture in USA (unspecified route)
  • 15 Apr 2005 Selective Genetics has ceased operations
  • 21 Aug 2003 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top